São Paulo - Delayed Quote BRL

Hypera S.A. (HYPE3.SA)

28.78 -0.23 (-0.78%)
At close: April 24 at 5:07 PM GMT-3
Loading Chart for HYPE3.SA
DELL
  • Previous Close 29.01
  • Open 0.00
  • Bid 28.72 x --
  • Ask 28.98 x --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 46.84
  • Volume 0
  • Avg. Volume 3,210,926
  • Market Cap (intraday) 18.219B
  • Beta (5Y Monthly) 0.35
  • PE Ratio (TTM) 11.11
  • EPS (TTM) 2.59
  • Earnings Date Apr 26, 2024
  • Forward Dividend & Yield 1.22 (4.18%)
  • Ex-Dividend Date Apr 24, 2024
  • 1y Target Est 42.96

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

www.hyperapharma.com.br

10,301

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HYPE3.SA

Performance Overview: HYPE3.SA

Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

HYPE3.SA
18.75%
IBOVESPA
7.04%

1-Year Return

HYPE3.SA
19.79%
IBOVESPA
19.52%

3-Year Return

HYPE3.SA
10.91%
IBOVESPA
3.49%

5-Year Return

HYPE3.SA
36.49%
IBOVESPA
30.04%

Compare To: HYPE3.SA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HYPE3.SA

Valuation Measures

Annual
As of 4/23/2024
  • Market Cap

    18.42B

  • Enterprise Value

    25.80B

  • Trailing P/E

    11.25

  • Forward P/E

    10.07

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.34

  • Price/Book (mrq)

    1.60

  • Enterprise Value/Revenue

    3.26

  • Enterprise Value/EBITDA

    8.97

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.82%

  • Return on Assets (ttm)

    6.48%

  • Return on Equity (ttm)

    14.89%

  • Revenue (ttm)

    7.91B

  • Net Income Avi to Common (ttm)

    1.65B

  • Diluted EPS (ttm)

    2.59

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.58B

  • Total Debt/Equity (mrq)

    88.38%

  • Levered Free Cash Flow (ttm)

    40.85M

Research Analysis: HYPE3.SA

Analyst Price Targets

33.00
42.96 Average
28.78 Current
56.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: HYPE3.SA

People Also Watch